Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Vertex (VERX) Tops Q2 Earnings and Revenue Estimates
09:21am, Wednesday, 07'th Aug 2024
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
Vertex Acquires ecosio To Accelerate Global E-Invoicing Compliance
07:07am, Wednesday, 07'th Aug 2024
Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance
Vertex Announces Second Quarter 2024 Financial Results
07:06am, Wednesday, 07'th Aug 2024
KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
04:31am, Tuesday, 06'th Aug 2024
Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive di
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
02:48pm, Friday, 02'nd Aug 2024
Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
01:48pm, Friday, 02'nd Aug 2024
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment
08:30am, Friday, 02'nd Aug 2024
Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis t
Hypergrowth Heroes: 7 Stocks That Could 10X Your Money
06:00am, Friday, 02'nd Aug 2024
Today we will be looking at hypergrowth stocks with the potential to 10X your investment. All but one of the stocks discussed below has achieved hypergrowth – growing by 40% or more – over the las
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
05:50am, Friday, 02'nd Aug 2024
There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.
Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments
04:09pm, Thursday, 01'st Aug 2024
Vertex Pharmaceuticals raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments.
Vertex Reports Second Quarter 2024 Financial Results
04:01pm, Thursday, 01'st Aug 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year product r
Is Vertex Pharmaceuticals' Monopoly in Danger?
08:15am, Thursday, 25'th Jul 2024
Vertex's dominance in the cystic fibrosis drug market could be challenged. Even in the worst-case scenario, its challenger's products won't be launched soon.
Google's Vertex AI to use Mistral AI's Codestral
10:02am, Wednesday, 24'th Jul 2024
Google Cloud will use Mistral AI's Codestral artificial intelligence model for Google's Vertex AI service, Google Cloud said on Wednesday.
Vertex Energy Provides Operational Update for Second Quarter 2024
05:00pm, Tuesday, 16'th Jul 2024
HOUSTON--(BUSINESS WIRE)--Vertex Energy, Inc. (NASDAQ:VTNR) ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, today provided an update to its fina
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
04:15am, Tuesday, 16'th Jul 2024
CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dolla
